HBHamza Naciri Bennani

Hamza Naciri Bennani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamza Naciri Bennani has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rheopheresis in hemodialysis patients with limb ulcers or amputation: safety and outcomes from a multicenter cohort

    by Yuri Bonsante, Cyril Ferdynus, Ehshaneraza Asgarali, Ludovic Di Ascia, Henri Vacher-Coponat, Asma Allal, Anabelle Baillet, Gabriel Gruget, Stéphanie Delelis, Reuben Veerapen, et al.

    Limb ulcers are common in hemodialysis (HD) and often have a poor prognosis despite standard care. Rheopheresis is a plasmapheresis technique that reduces

  • Open Access

    Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience

    by Hamza Naciri Bennani, Thomas Sandaye, Quentin Charroyer, Aurelie Etangsale, Henri Vacher Coponat, Marie Julien, Vincent Mear, Olivier Dunand, Ludovic Di Ascia

    Background: Refractory idiopathic nephrotic syndrome (INS), in native kidneys or post-transplant, represents a major therapeutic challenge due to its high risk of progressing to end-stage renal disease. Patients often resist anti-CD20 therapy and require prolonged apheresis. Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has demonstrated promising efficacy in case reports when combined with anti-CD20, but evidence remains limited. Methods: We conducted a single-center retrospective study including four patients (two pediatric, two adult, including one renal transplant) with INS refractory to conventional therapies (corticosteroids, calcineurin inhibitors, mycophenolate mofetil, anti-CD20 antibodies, and/or apheresis). All Patients received daratumumab combined with anti-CD20 therapy at University Hospital of La Réunion between 2022 and 2025. Clinical and laboratory data were extracted from medical records. Renal response was defined as complete remission (CR) or partial remission (PR). Results: The mean patient age was 20 ± 13 years (range: 8–40), with a male-to-female ratio of 3:1. Median follow-up after daratumumab administration was 5 months (range: 2–12). All patients achieved CR with a median time to response of 25 days (range: 14–30). Previously apheresis-dependent patients were able to discontinue sessions. Two patients developed infections (herpetic and SARS-CoV-2 pneumonia complicated by pneumococcal bacteremia), all resolving favorably. Renal function remained stable. Conclusion: Combined daratumumab and anti-CD20 therapy appears to be an effective rescue strategy for refractory INS, in native kidneys and post-transplant. It induces rapid and sustained remission, enabling discontinuation of apheresis. Prospective studies are warranted to optimize treatment regimens and identify predictive biomarkers of response.